NTRK1 and neoplasm: Considering that TrkAIII is a potentially actionable TrkA-fused oncogene equivalent and that alternative TrkAIII splicing is pronounced and occasionally exclusive in advanced-stage, metastatic and relapsed NBs, PRCs, MTC, GBs, MCCs, CMMs, and PitNET tumors [16,17,20,25,26,27,28], and considering the current lack of a TrkAIII-specific real-time qPCR detection method, we have developed a sensitive TrkAIII-specific TaqMan-based qRT-PCR assay for quantifying TrkAIII expression in complex tumor cDNAs.